2024
Portable, low-field magnetic resonance imaging for evaluation of Alzheimer’s disease
Sorby-Adams A, Guo J, Laso P, Kirsch J, Zabinska J, Garcia Guarniz A, Schaefer P, Payabvash S, de Havenon A, Rosen M, Sheth K, Gomez-Isla T, Iglesias J, Kimberly W. Portable, low-field magnetic resonance imaging for evaluation of Alzheimer’s disease. Nature Communications 2024, 15: 10488. PMID: 39622805, PMCID: PMC11612292, DOI: 10.1038/s41467-024-54972-x.Peer-Reviewed Original ResearchConceptsWhite matter hyperintensitiesMachine learning pipelineMild cognitive impairmentAlzheimer's diseaseWhite matter hyperintensities volumeLearning pipelineAssessment of patientsIncrease accessCognitive impairmentEvaluation of Alzheimer's diseaseDementiaLF-MRIPoint-of-care assessmentMagnetic resonance imagingHippocampal volumeResonance imagingImage qualityDiseaseReduce costsAnisotropic counterpartIncreasing availabilityManual segmentation
2021
Increased Blood Pressure Variability and the Risk of Probable Dementia or Mild Cognitive Impairment: A Post Hoc Analysis of the SPRINT MIND Trial
de Havenon A, Anadani M, Prabhakaran S, Wong K, Yaghi S, Rost N. Increased Blood Pressure Variability and the Risk of Probable Dementia or Mild Cognitive Impairment: A Post Hoc Analysis of the SPRINT MIND Trial. Journal Of The American Heart Association 2021, 10: e022206. PMID: 34533059, PMCID: PMC8649507, DOI: 10.1161/jaha.121.022206.Peer-Reviewed Original ResearchConceptsBlood pressure controlBlood pressure variabilityMild cognitive impairmentCognitive impairmentProbable dementiaMIND trialBlood pressurePressure variabilityExcellent blood pressure controlPressure controlSuboptimal blood pressure controlSystolic blood pressure variabilityCox proportional hazards modelRisk of dementiaBlood pressure measurementsProportional hazards modelRate of dementiaPost Hoc AnalysisLowest tertileHighest tertilePrimary outcomeCardiovascular diseaseHoc AnalysisCox modelHazards model
2019
Is There Equipoise Regarding the Optimal Medical Treatment of Patients with Asymptomatic White Matter Hyperintensities?
de Havenon A, Prabhakaran S, Turan T, Gottesman R, Yeatts S, Rost N. Is There Equipoise Regarding the Optimal Medical Treatment of Patients with Asymptomatic White Matter Hyperintensities? Journal Of Stroke And Cerebrovascular Diseases 2019, 28: 104371. PMID: 31495669, PMCID: PMC8015436, DOI: 10.1016/j.jstrokecerebrovasdis.2019.104371.Peer-Reviewed Original ResearchMeSH KeywordsAntihypertensive AgentsAsymptomatic DiseasesAttitude of Health PersonnelDisease ProgressionHealth Care SurveysHealth Knowledge, Attitudes, PracticeHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLeukoencephalopathiesNeurologistsPlatelet Aggregation InhibitorsPractice Patterns, Physicians'Therapeutic EquipoiseTreatment OutcomeConceptsAsymptomatic white matter hyperintensitiesWhite matter hyperintensitiesOptimal medical treatmentMatter hyperintensitiesMedical treatmentCognitive impairmentIntensive Blood Pressure ReductionNeurologists' attitudesBlood pressure targetsStroke prevention therapyBlood pressure reductionOptimal medical managementRegional coordinating centersMild cognitive impairmentStatin therapyIschemic strokeMicrovascular diseasePressure targetsPrevention therapyClinical outcomesFunctional disabilityMedical managementPatient populationCommon manifestationWMH progression